CRTC1 and anemia: Toxicities of fatigue, nausea, anaemia, and diarrhoea in this dose-escalation cohort were not dissimilar to previous studies combining m-TOR inhibitors such as everolimus [12], ridaforolimus [13], or the m-TORC1/2 inhibitor, MLN028 [14], with weekly paclitaxel regimens.